Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060475 | 0.87 | ALDH1A1 (0.40) | ENPP2CA2CA12CA9CA1 | |
| SCHEMBL10060466 | 0.80 | CA12 (0.46) | LMNACA2CA12CA9CA1 | |
| SCHEMBL2918280 | 0.79 | ENPP2 (0.48) | ENPP2LMNACA2CA12CA9 | |
| SCHEMBL14520771 | 0.78 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL178444 | 0.78 | GAA (0.56) | LMNACA2CA12CA9CA1 | |
| SCHEMBL2657775 | 0.78 | ALDH1A1 (0.36) | CA2CA12CA9CA1GAA | |
| SCHEMBL5325314 | 0.77 | NR1I2 (0.39) | LMNACA2CA12CA9CA1 | |
| SCHEMBL27834966 | 0.77 | ENPP2 (0.47) | ENPP2LMNACA2CA12CA9 | |
| SCHEMBL1368959 | 0.76 | CA1 (0.48) | CA2CA1ALDH1A1TP53MAPT | |
| SCHEMBL2646286 | 0.76 | CA1 (0.47) | CA2CA12CA9CA1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | claimed |
| CN-101821276-B | Novel glucokinase activators | 症变治疗公司 | 2016-08-31 | — | — | CN | claimed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | claimed |
| EP-2185570-B1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | claimed |
| JP-2010536773-A | — | — | 2010-12-02 | — | — | JP | claimed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2022-01-06 | — | — | US | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARP15 | ENPP2 313/4885LMNA 864/4885CA2 2287/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | ENPP2 2324/4885LMNA 3764/4885CA2 532/4885 |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | ENPP2 628/4885LMNA 1162/4885CA2 3337/4885 |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | ENPP2 1210/4885LMNA 3822/4885CA2 5/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | ENPP2 748/4885LMNA 1099/4885CA2 3607/4885 |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | ENPP2 3278/4885LMNA 3434/4885CA2 893/4885 |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | ENPP2 2324/4885LMNA 3764/4885CA2 532/4885 |
| US-11858879-B2 | PARG inhibitors and method of use thereof | PARG, PARP12, PARP15 | ENPP2 313/4885LMNA 864/4885CA2 2287/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | ENPP2 2371/4885LMNA 3697/4885CA2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.